Abbott Laboratories (ABT)
Coverage summary
Aardvark Labs Capital Research has covered Abbott Laboratories (ABT) since July 18, 2025. The company is in the Healthcare sector. This page lists 6 reports: 6 earnings recaps.
The latest is the Q3 2026 Earnings Recap, published October 25, 2026. The current rating is Outperform, unchanged since the Q4 2025 Earnings Recap of January 23, 2026. The rating has changed once since coverage began.
Translations: 5 in Chinese.
Rating history
All ABT reports
Recap: Q3 2026
Abbott Spins Off Nutrition and Trims Its Sales Guide as CGM Pricing Bites, but a 7% Quarter Keeps the Thesis Alive
Recap: Q2 2026
The Acceleration Arrives: Abbott Beats, Raises, and Rips 11% as the Ex-Deal Growth Question Resolves
Recap: Q1 2026
The Plan Is Working, the Stock Isn't: Exact Sciences Closes, EP Accelerates, Nutrition Volume Turns — Maintaining Outperform at a Fresh Low
Recap: Q4 2025
A Nutrition Air Pocket Sparks a 10% Drop; the EPS Algorithm, a Diagnostics Inflection, and Exact Sciences Are Intact — Upgrading to Outperform
Recap: Q3 2025
An In-Line Quarter, a Confident 2026 Preview, and an Upgrade on Deck: Maintaining Hold
Recap: Q2 2025
A Beat the Tape Hated: The Device Engine Roars, Diagnostics Drags, and a Trimmed Guide Ceiling Resets a Premium Multiple — Initiating at Hold